HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme.

摘要

The next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine (formerly known as TMC125) has shown efficacy in the DUET trials in combination with a background regimen of darunavir with low-dose ritonavir (DRV/r), nucleoside analogue reverse transcriptase inhibitors (NRTIs) and optional enfuvirtide (ENF). In the DUET trials, the percentage of patients with HIV RNA suppression <50 copies/mL was highest for patients who harboured virus sensitive to etravirine, and who combined etravirine with other active drugs in the background regimen.3 Similar trends have been found in the BENCHMRK trials with the integrase inhibitor raltegravir,4and in the MOTIVATE trials with the CCR5 antagonist maraviroc. Clinical pharmacology studies support the use of etravirine in combination with DRV/r,6 raltegravir7 or maraviroc.Recent studies have evaluated the efficacy and safety of etravirine in combination with several combinations of these drugs:these studies have shown high rates of efficacy after 24 weeks of follow-up.